MUC4 and lung adenocarcinoma: Our immunohistochemistry (IHC) studies have revealed that a high MUC1/SP-A ratio is strongly associated with a poor outcome in patients with small-size lung adenocarcinoma and that high MUC4 expression in lung adenocarcinoma patients associates with poor outcome [12–14].